Skip to main content
International
Ask us anything:
  • About
        • About We challenge convention so healthy can be possible
        • Our Story
          • Amneal at-a-glance
          • Our Founders
          • Our Milestones
        • Our Purpose & Commitments
        • Our Culture
          • Rise, Lead, Succeed
        • Our Leadership
          • Executive Leadership
          • Board of Directors
        • Our Locations
        • Responsibility
          • The Amneal Patient Assistance Programs
          • Product Donations
          • National & Local Philanthropy
          • Compliance and Ethics
        • Patient Community Connections
          • Our Commitment to Parkinson's
        • Awards & Recognition
  • Products
        • Products We create essential medicines
        • Our Portfolio
          • Biosciences
          • Generic Products
          • Specialty Products
          • Product Catalog
        • Quality
        • Drug Safety
          • Adverse Event Reporting
          • Medical Inquiries
          • Product Complaints
        • Operations
  • Research & Development
        • Research & Development We invest significantly in new product development
        • Generics R&D
        • Specialty R&D
          • Drug Delivery Technologies
        • Product Partnering
  • Investors
        • Investors Become an Informed Investor
  • News
  • Careers
        • Careers Help make healthy possible
        • Total Rewards
        • Search Our Career Opportunities
  • Contact
  • Customer Login
Amneal Pharmaceuticals
  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds

Home Home  >  News  >  Press Releases

  • Investor Relations
  • Financial Reports
    • SEC Filings
    • Annual Reports
    • Quarterly & Other Reports
  • Events & Presentations
  • Stock Information
  • Corporate Governance
    • Policies
    • Executive Officers & Directors
    • Board Committees
  • Investor Resources
    • Analysts
    • Investor FAQ
    • Email Alerts
    • Information Request
    • RSS Feeds
Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002
Nov 11, 2020
Amneal Receives Abbreviated New Drug Application Approval for Acyclovir Cream, 5%
Nov 06, 2020
Amneal Reports Third Quarter 2020 Financial Results
Oct 15, 2020
Amneal to Report Third Quarter 2020 Results on November 6, 2020
Oct 08, 2020
Amneal & PL Developments Launch Store Brand Program of Over-the-Counter (“OTC”) Diclofenac Sodium Topical Gel, 1%
Sep 01, 2020
Amneal to Virtually Participate at the Morgan Stanley Global Healthcare Conference
Aug 25, 2020
Amneal Receives Abbreviated New Drug Application Approval for Lidocaine Patch, 5%
Aug 06, 2020
Amneal Reports Second Quarter 2020 Financial Results
Jul 10, 2020
Amneal Launches Generic Fluphenazine Following ANDA Approval by FDA
Jul 08, 2020
Amneal to Report Second Quarter 2020 Results on August 6, 2020
Jun 03, 2020
Amneal Pharmaceuticals LLC Issues Voluntary Nationwide Recall of Metformin Hydrochloride Extended Release Tablets, USP, 500 mg and 750 mg, due to Detection of N-Nitrosodimethylamine (NDMA) Impurity to Consumer Level
May 11, 2020
Amneal Reports First Quarter 2020 Financial Results
Apr 24, 2020
Amneal to Report First Quarter 2020 Results on May 11, 2020
Apr 16, 2020
Amneal Launches Generic Butrans® Following ANDA Approval by FDA
Apr 15, 2020
Amneal Pharmaceuticals Moving to a Virtual Meeting Format for 2020 Annual Meeting of Stockholders
Apr 15, 2020
Amneal Pharmaceuticals, LLC. Issues Voluntary Nationwide Recall of Nizatidine Oral Solution, 15 mg/mL, Due to Potential Levels of N-nitrosodimethylamine (NDMA) Impurity amounts above the levels established by FDA
Mar 26, 2020
State of Texas and Senator Bryan Hughes Secure a Donation of Hydroxychloroquine Sulfate from Amneal Pharmaceuticals for Texas Patients
Mar 20, 2020
Amneal Accelerates Distribution and Production of Hydroxychloroquine Sulfate to Meet Potential Needs of COVID-19 Patients Nationwide
Mar 11, 2020
Amneal Pharmaceuticals Appoints Tasos Konidaris as Senior Vice President, Chief Financial Officer
Feb 26, 2020
Amneal Reports Fourth Quarter and Full Year 2019 Financial Results
Jan 24, 2020
Amneal to Report Fourth Quarter and Full Year 2019 Results on February 26, 2020

Investor Faq

Get answers to important investor relation questions.

More

Investor Tools

  • Email Alerts
  • RSS Feeds
  • Email Page

IR Contact

Get answers to your investor relation questions.

More
  • Privacy Policy
  • Copyright & Legal Disclaimer
  • Web Accessibility
© Amneal Pharmaceuticals LLC.
All rights reserved.
Powered By Q4 Inc. 5.86.0.1 (opens in new window)
Back to top